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ABSTRACT
Programmed cell death ligand 1 (PD-L1) is a cell surface glycoprotein that 
regulates the cellular immune response and serves as a targetable immune checkpoint 
molecule. PD-L1 is expressed on tumor cells and the immune microenvironment of 
several human malignancies, including a subset of aggressive lymphomas. We sought 
to investigate further the clinical and pathologic features of EBV-negative diffuse 
large B-cell lymphoma (DLBCL) cases that express PD-L1. Immunohistochemical 
staining using an anti-PD-L1 monoclonal antibody was performed on DLBCL cases 
from 86 patients. These patients received standard chemotherapy treatment and were 
followed for up to 175 months. Overall, 14 cases (16%) were considered positive for 
PD-L1 in tumor cells. In comparison with PD-L1 negative cases, PD-L1 positive cases 
had a higher rate of non-GCB type (71% vs. 30%, P=0.0060), and higher Ann Arbor 
stage (II-IV) (100% vs. 73%, P=0.0327). No significant differences were seen in 
the immunohistochemical expression of BCL2, MYC, or Ki67. Patients with tumors 
expressing PD-L1 demonstrated inferior overall survival (OS) upon long term follow 
up (P=0.0447). Both age/sex-adjusted and multivariate analyses identified PD-L1 as 
an independent predictor for OS (P=0.0101 and P=0.0424). There was no significant 
difference, however, in terms of remission rates after first treatment, relapse rates, 
and progression free survival between the groups. Identification of DLBCL cases that 
express PD-L1 may serve to select a subset of patients that could further benefit from 
targeted immunotherapy.
INTRODUCTION
Immune checkpoint blockade strategies have 
revolutionized the approach to cancer therapy and 
have provided oncologists and patients with novel 
therapeutic options for a range of malignancies [1]. 
Immunotherapeutic targeting of hematologic malignancies, 
most notably classical Hodgkin lymphoma, have recently 
centered on disrupting the programmed death-1 (PD-1) 
immunomodulatory pathway [2, 3]. Binding of PD-1 by its 
cognate receptors PD-L1 and PD-L2 inhibits proliferation 
of activated T cells in peripheral tissues leading to “T-cell 
exhaustion,” a functional phenotype that can be reversed 
by PD-1 blockade [4]. Immunohistochemical detection of 
PD-L1 has been well-documented in a range of human 
malignancies, including aggressive EBV-positive B-cell 
lymphomas [5], classical Hodgkin lymphoma [6, 7], 
melanoma, renal cell carcinoma, and non-small cell lung 
carcinoma [8]. Interestingly, PD-L1 expression has been 
observed on tumor cells as well as on non-malignant 
infiltrating histiocytes, suggesting tumors may elicit an 
overall immunosuppressive microenvironment as a means 
of tumorigenesis [5].
These findings have provided a rationale for 
disrupting the PD-1 axis using antibodies against 
these antigens with the objective of restoring the anti-
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tumor activity of suppressed T cells. Clinical trials with 
humanized monoclonal antibodies against PD-L1 and 
PD-1 have yielded robust, durable responses in patients 
with advanced malignancies including metastatic 
melanoma, tumors with mismatch-repair deficiency, and 
relapsed or refractory classical Hodgkin lymphoma [9-
12]. Responses have also been reported in smaller series 
of hematologic malignancies, including acute myeloid 
leukemia, follicular lymphoma, and a number of cases of 
diffuse large B-cell lymphoma (DLBCL) [13-15]. Notably, 
in a subset of cases examined, clinical responsiveness to 
PD-1 blockade correlated with tumor-specific expression 
of PD-L1 as detected by immunohistochemistry (IHC) [8, 
12].
DLBCL, not otherwise specified (NOS), is the most 
common type of non-Hodgkin lymphoma among adults 
and is both clinically and pathologically heterogeneous. 
Several pathologic features are known to predict a 
worse clinical outcome for DLBCL patients, including 
non-germinal center B-cell (non-GCB) phenotype 
[16], increased MYC protein expression [17], and gene 
rearrangements involving BCL2, BCL6, and/or MYC [18-
20]. Identifying additional features that could predict 
potential response to immunotherapy is important to 
both understanding the immunomodulatory mechanisms 
of hematologic malignancies and to developing novel 
chemotherapeutic regimens.
In the present study, we sought to investigate further 
the clinical and pathologic features of EBV-negative 
DLBCL cases with PD-L1 expression. Using a well-
annotated cohort of patients with treatment information 
and long term clinical follow-up, we examined the 
immunohistochemical expression of PD-L1 in tumor cells 
and the microenvironment, and correlated these data with 
additional histologic parameters and clinical outcome data.
RESULTS
Pathologic characteristics
PD-L1-positive tumor cells, along with PD-
L1-positive non-malignant cells, were recorded as a 
percentage of the total cellularity within tumor sections 
(Figure 1). A threshold of >30% PD-L1-positive tumor 
cells captured the majority of cases that exhibited positive 
PD-L1 staining (14/27, 52%), similar to the findings of 
a recent study [21]. Of the 86 DLBCL cases, 14 cases 
(16%) were considered PD-L1 positive cases based on 
this threshold. Of the 72 PD-L1 tumor negative cases, 23 
cases (27%) showed at least 5% PD-L1 positive staining 
in the non-malignant cells (mPD-L1 positive, Figure 1). 
Representative photographs of DLBCL cases stained with 
PD-L1 IHC with corresponding scores are shown in Figure 
2. Eighty-three cases had evaluable material to be further 
subcategorized into GCB and non-GCB types according 
to the cell-of-origin (COO) Hans algorithm [16]. Out of 
14 PD-L1 positive cases, 4 cases (29%) were GCB type 
and 10 cases (71%) were non-GCB type. Out of 69 PD-




























Figure 1: PD-L1 scores in lymphoma cells and microenvironment of 86 DLBCL cases. Graphical representation of the 
percentage of total cells within the tissue section staining positive with anti-PD-L1, and showing the contributions of malignant cells (white 





Figure 2: PD-L1 expression detected by immunohistochemical staining in DLBCL. A. Negative staining. B. Tumor cells 
negative for PD-L1 but histiocytes in the microenvironment staining positive, about 10% of the total cellularity. C. Tumor cells showing 
strong membrane positivity for PD-L1. Original magnification: 400x.
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cases (30%) were non-GCB type. PD-L1 positive cases 
had a higher rate of non-GCB phenotype compared to PD-
L1 negative cases (71% vs. 30%, P=0.0060, Table 1).
The overall positivity rates of CD10, BCL2, BCL6, 
and MUM1 were 36%, 58%, 62%, and 53%, respectively. 
MYC positive tumor cells by IHC ranged from 0% to 
80% (mean ± SD, 28.3±25.3%). The Ki67 labeling index 
ranged from 10% to 95% (mean±SD, 56.2±26.2%). 
CD10, BCL6, and MUM1 showed significant differences 
between the PD-L1 positive and negative groups reflecting 
the non-GCB vs. GCB phenotype differences (Table 1). 
When comparing the immunohistochemical expression of 
BCL2, MYC, or Ki67 between the PD-L1 positive and 
PD-L1 negative groups, no significant differences were 
seen (Table 1). Separate analysis of mPD-L1 positive vs 
mPD-L1 negative cases showed no significant differences 
in these IHC studies.
Clinical characteristics
Clinical features including age, gender, presence 
of B symptoms, pre-treatment LDH, IPI score, and bone 
marrow involvement showed no statistical difference 
between PD-L1 positive and negative groups (Table 2). 
The total extralymphatic organ (organs other than bone 
marrow, lymph node and spleen) involvement rate was 
59% (46/78, Table 2). Both the PD-L1 tumor positive 
group (10/12, 83%) and mPD-L1 positive group (17/20, 
85%) showed greater extralymphatic organ involvement 
compared to the mPD-L1 negative group (19/46, 41%), 
which was statistically significant (P=0.0206 and 
P=0.0012 respectively, Table 2). The rates of high Ann 
Arbor stage (II-IV) at diagnosis of mPD-L1 negative, 
mPD-L1 positive and PD-L1 positive cases were 67% 
(30/45), 86% (18/21) and 100% (13/13), respectively. PD-
Table 1: Pathologic features of DLBCL cases with PD-L1 expression
Pathologic Features PD-L1 positive
PD-L1 negative
Total PΦ P# P†
mPD-L1-positive mPD-L1-negative
Phenotype
  GCB 4 (29%) 13 (57%) 35 (76%) 52 0.0060* 0.1067 0.0027*
  Non-GCB 10 (71%) 10 (43%) 11 (24%) 31
BCL2
  Positive (>30%) 11 (79%) 15 (71%) 24 (51%) 50 0.2283 0.1841 0.1220
  Negative 3 (21%) 6 (29%) 23 (49%) 32
BCL6
  Positive (>30%) 5 (36%) 16 (76%) 32 (70%) 53 0.0146* 0.7714 0.0306*
  Negative 9 (64%) 5 (24%) 14 (30%) 28
CD10
  Positive 1 (7%) 7 (32%) 23 (49%) 31 0.0134* 0.2041 0.0050*
  Negative 13 (93%) 15 (68%) 24 (51%) 52
MUM1
  Positive (>30%) 13 (93%) 12 (55%) 21 (48%) 46 0.0029* 0.7944 0.0040*
  Negative 1 (7%) 10 (45%) 23 (52%) 34
MYC
  < 40% 7 (50%) 11 (48%) 34 (74%) 52 0.3659 0.0590 0.1108
  ≥ 40% 7 (50%) 12 (52%) 12 (26%) 31
Ki67
  < 80% 10 (71%) 14 (61%) 34 (71%) 58 0.7789 0.4275 1.0000
  ≥ 80% 4 (29%) 9 (39%) 14 (29%) 27
Fisher’s exact test. *: P value is significant (<0.05); PΦ: PD-L1-positive versus PD-L1-negative; P#: mPD-L1-positive versus 
mPD-L1-negative; P†: PD-L1-positive versus mPD-L1-negative.
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Table 2: Clinical features of DLBCL cases with PD-L1 expression
Clinical Features PD-L1 positive
PD-L1 negative
Total PΦ P# P†
mPD-L1-positive mPD-L1-negative
Age (years)
  ≤ 60 5 (36%) 5 (22%) 14 (29%) 24 0.5216 0.7749 0.7428
  > 60 9 (64%) 18 (78%) 35 (71%) 62
Gender
  Male 7 (50%) 15 (65%) 18 (37%) 40 0.7793 0.0413* 0.5367
  Female 7 (50%) 8 (35%) 31 (63%) 46
B symptoms
  Presence 2 (25%) 3 (18%) 12 (33%) 17 1.0000 0.3332 1.0000
  Absence 6 (75%) 14 (82%) 24 (67%) 44
Pre-treatment LDH
  Normal 2 (20%) 11 (58%) 15 (36%) 28 0.2961 0.1618 0.4668
  Elevated 8 (80%) 8 (42%) 27 (64%) 43
IPI score
  0 - 1 1 (10%) 7 (41%) 13 (30%) 21 0.2621 0.5438 0.2634
  2 - 5 9 (90%) 10 (59%) 31 (70%) 50
Ann Arbor Stage
  I 0 (0%) 3 (14%) 15 (33%) 18 0.0327* 0.1423 0.0138*
  II - IV 13 (100%) 18 (86%) 30 (67%) 51
BM involvement
  Present 3 (30%) 3 (19%) 2 (6%) 8 0.1309 0.3164 0.0782
  Absent 7 (70%) 13 (81%) 30 (94%) 50
Extralymphatic involvement
  Present 10 (83%) 17 (85%) 19 (41%) 46 0.1083 0.0012* 0.0206*
  Absent 2 (17%) 3 (15%) 27 (59%) 32
Complete and partial remission after first treatment
  Yes 5 (71%) 18 (86%) 33 (75%) 56 0.6473 0.5200 1.0000
  No 2 (29%) 3 (14%) 11 (25%) 16
Relapse after initial treatment
  Yes 9 (82%) 10 (56%) 31 (69%) 50 0.4861 0.3850 0.4829
  No 2 (18%) 8 (44%) 14 (31%) 24
Outcome
  Dead 9 (82%) 8 (47%) 26 (59%) 43 0.1806 0.5662 0.2932
  Alive 2 (18%) 9 (53%) 18 (41%) 29
Fisher’s exact test. *: P value is significant (<0.05); PΦ: PD-L1-positive versus PD-L1-negative; P#: mPD-L1-positive versus 
mPD-L1-negative; P†: PD-L1-positive versus mPD-L1-negative.
Oncotarget59981www.impactjournals.com/oncotarget
L1 positive cases had significantly higher initial staging 
than PD-L1 negative cases (P=0.0327).
The majority of patients (73/86, 85%) received 
rituximab, cyclophosphamide, doxorubicin, vincristine and 
prednisone (R-CHOP) as standard chemotherapy. Other 
treatment regimens included dose-adjusted etoposide, 
vincristine, doxorubicin, cyclophosphamide and prednisone 
(EPOCH); hyper-fractionated cyclophosphamide, 
vincristine, doxorubicin and dexamethasone (hyper-
CVAD); chlorambucil plus prednisone; rituximab alone; 
methotrexate alone; and radiation alone. None of the 
patients received hematopoietic stem cell transplant. 
All patients were followed by clinical and radiological 
assessments over a period ranging from 2 days to 175 
months (median follow-up 21 months).
Of 72 patients who received R-CHOP treatment and 
had available followup information, the overall response 
rate (complete and partial remission) was 78% (56/72). No 
significant differences were found among the three groups 
(Table 2).
After initial treatment, the median progression-free 
survival (PFS) time was 18.5 months (range, 2 days to 173 
months) and the median overall survival (OS) time was 
21 months (range, 2 days to 174 months). For survival 
analyses, the 86 cases were divided into 2 groups: PD-L1 
positive and PD-L1 negative groups (including mPD-L1 
positive and mPD-L1 negative cases). Kaplan-Meier 
curves of PFS and OS showed apparent decreased survival 
of the PD-L1 positive group (Figure 3), although only 





=0.0447). Within the PD-L1 
negative group, there was no significant difference in OS 






Figure 3: Survival curves for progression-free survival and overall survival. Kaplan-Meier curves for A. progression-free 
survival (PFS) time (P=0.0773) and B. overall survival (OS) time (P=0.0447) among PD-L1 positive and PD-L1 negative cases.
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Age and sex-adjusted Cox regression analysis of 
prognostic factors for OS revealed PD-L1 expression 
(P=0.0101), high stage (II-IV) (P=0.0064), and 
intermediate-high IPI (2-5) (P=0.0120) were statistically 
significant predictors of OS (Table 3). Non-GCB type 
was also an unfavorable factor with borderline statistical 
significance (P=0.0657). In a multivariate model 
examining these factors, PD-L1 expression remained a 
statistically significant factor for OS (P=0.0424) (Table 3).
DISCUSSION
Immune checkpoint blockade therapy is a promising 
chemotherapeutic strategy that will likely lead to novel 
multimodal and combinatorial approaches to treating 
hematologic malignancies [1]. In the case of B-cell non-
Hodgkin lymphoma, limited but encouraging results 
have been observed in early clinical trials [13-15]. In 
many of the recent clinical trials of anti-PD1/PDL1 
immunotherapy, PD-L1 expression in tumor cells was not 
used as a prerequisite for patient enrollment. Retrospective 
analyses, however, have shown that PD-L1 positivity in 
tumor cells, as detected by immunohistochemistry, may 
predict improved response to anti-PD1/PD-L1 therapy 
in melanoma, non-small cell lung carcinoma, renal cell 
carcinoma, and urothelial carcinoma [8, 12, 22]. Thus, 
profiling tumors for PD-L1 expression may aid in the 
rational selection of patients for whom immunotherapy 
may be expected to provide a more robust response.
In this study, we correlated PD-L1 expression in 
EBV-negative DLBCL cases with clinical and pathologic 
features. In our cohort, 16% of cases were positive for 
PD-L1 in tumor cells and an additional 27% had positive 
microenvironment staining. Several recent studies have 
examined the incidence of PD-L1 positivity in DLBCL, 
NOS cases and variants of DLBCL, including T-cell/
histiocyte-rich large B-cell lymphoma and EBV-positive 
DLBCL of the elderly [5, 21, 23-25]. The proportion of 
DLBCL, NOS cases in our study that was positive for PD-
L1 was comparable to that seen in these previous studies 
examining similar cohorts of DLBCL cases. Furthermore, 
we confirm previous observations that PD-L1 positive 
DLBCL cases were more commonly of the non-germinal 
center B-cell type, which typically portends a poorer 
overall prognosis. In addition, PD-L1 expression was not 
significantly associated with other prognostic features 
such as BCL2 or Ki67 proliferation index.
In addition to non-GCB phenotype, we found that 
patients with PD-L1 positive DLBCL had higher-stage 
tumors than those with PD-L1 negative DLBCL. We 
also found a trend towards poorer outcomes in terms of 
PFS and OS for patients with PD-L1 positive tumors. 
Decreased OS was found to be statistically significant in 
our cohort. Two analyses of clinical outcome in PD-L1 
positive DLBCL have recently been reported [21, 25]. 
Kiyasu, et al [21], examined a cohort of 1253 DLBCL 
cases and found that, in a smaller subset of cases with 
available clinical data (273 cases), PD-L1 positivity 
in tumor cells correlated with poorer overall survival. 
This cohort included cases of DLBCL, NOS, as well as 
variants such as EBV+ DLBCL. In this study, a threshold 
of >30% of tumor cells positive for PD-L1 was identified 
based upon the observation that the majority of cases were 
captured by this analysis. In the current study, we find that 
a similar threshold appears to identify a cohort of DLBCL 
cases that also have poorer overall survival providing an 
important external validation of the prior findings and 
supporting the use of this threshold. Another recent study 
by Kwon, et al [25], examined 126 DLBCL cases. This 
cohort included cases of DLBCL, NOS, as well as EBV+ 
DLBCL cases. In this study, a threshold of 10% PD-L1 
positivity was used, yielding about 30% of DLBCL cases 
with at least moderate staining. No significant correlation 
with patient outcome was seen in this analysis.
Among the studies examining PD-L1 expression 
in DLBCL, it should be noted that the thresholds for 
determining PD-L1 positivity have varied widely. In earlier 
studies of PD-L1 staining in DLBCL, a lower threshold, 
such as 5% tumor positivity, was employed [5], similar 
to that used for the early studies of PD-L1 expression in 
melanoma [8]. In terms of predicting prognosis, it seems 
Table 3: Prognostic factors affecting the OS of patients with EBV- DLBCL
Characteristic
Age- and sex-adjusted analysis Multivariate analysis#
HR (95% CI) P HR (95% CI) P
PD-L1+ vs. PD-L1- 2.740 (1.272 – 5.904) 0.0101* 2.418 (1.031 – 5.670) 0.0424*
Non-GCB vs. GCB 1.824 (0.962 – 3.460) 0.0657 1.321 (0.640 – 2.730) 0.4517
Stage II-IV vs. Stage I 4.318 (1.508 – 12.362) 0.0064* 3.125 (0.880 – 11.101) 0.0781
IPI intermediate-high 
vs IPI low 3.949 (1.353 – 11.523) 0.0120* 2.961 (0.823 – 10.658) 0.0967
*: P value is significant (<0.05).
#: The variables included in multivariate analysis for OS were age, sex, expression of PD-L1, cell of origin, stage, and IPI.
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that higher expression levels, such as 30%, as seen in the 
study by Kiyasu, et al, and our study, may be more relevant 
to identifying patients at risk of poorer clinical outcome. 
In our study, we found that lowering the cutoff threshold 
to 5, 10, or 20% resulted in non-statistically significant 
survival differences (data not shown). The study by Kwon, 
et al, further highlights the potentially tenuous relationship 
between PD-L1 expression and prognosis in DLBCL. 
A limitation to any proposed cutoff value for PD-L1 
positivity is the inherently subjective nature of evaluating 
immunohistochemical staining. Computer aided 
detection and double-staining techniques may assist in 
the evaluation, but these approaches may not be practical 
for routine clinical use and carry their own limitations. 
Further complicating these analyses is the heterogeneous 
nature of the DLBCL, NOS category, and the inclusion of 
variants such as EBV+ cases in the cohorts examined in 
the studies by Kiyasu, et al, and Kwon, et al. In our study, 
we have limited our cohort to EBV-negative DLBCL in 
an effort to exclude the influence of EBV positivity on 
prognosis. Nonetheless, several studies have found that 
PD-L1 expression in a wide range of different solid tumor 
types, including breast [26], bladder [27], stomach [28], 
and non-small cell lung carcinoma [29] correlates with 
poorer prognosis [30]. Clearly, better-powered studies 
involving larger patient populations receiving standardized 
chemotherapy regimens and long-term followup are 
needed to build upon these compelling findings.
The finding that a subset of DLBCL cases had PD-
L1 expression in non-malignant cells within the tumor 
microenvironment supports previous studies that observed 
a distinct proportion of classical Hodgkin lymphoma and 
DLBCL with this finding [5]. In our cohort, this finding 
did not translate into a significant prognostic factor, 
as was found by Kiyasu, et al [21]. The mechanisms 
responsible for the upregulation of PD-L1 in the tumor 
microenvironment need further investigation, but are an 
intriguing source of tumor-induced immunomodulation 
that could potentially be targeted.
In the case of classical Hodgkin lymphoma, at least 
two independent genetic mechanisms, 9p24 amplification 
and EBV infection, are thought to lead to overexpression 
of PD-L1 in the malignant Reed-Sternberg cells [6, 7]. 
Similarly, the majority of EBV-positive aggressive B-cell 
lymphomas, including EBV-positive DLBCL, show 
upregulation of PD-L1 [5]. For DLBCL-NOS, a recent 
study identified a genetic basis of PD-L1 overexpression 
through translocations between the PD-L1 and IGH gene 
loci [31]. These cases may represent a distinct subtype of 
DLBCL that will require further characterization.
With the anticipation of additional clinical trials 
of immunotherapy directed at the PD-1 axis, treatment 
challenges will include determining the ideal time to 
initiate targeted immunotherapy; whether to combine 
immunotherapy with conventional chemotherapy, other 
immune checkpoint inhibitors, or hematopoietic stem cell 
transplant; and whether treatment should be continued 
following the first remission to prevent recurrence. 
Identification of DLBCL cases that express PD-L1 may 
form a rational basis for guiding therapy and can serve 
to select a subset of patients that could further benefit 
from targeted immunotherapy. Threshold levels of PD-L1 
expression will need to be further examined to determine 
a biologically relevant level of expression that can predict 
tumor response to therapy and/or predict patient prognosis.
MATERIALS AND METHODS
Case selection
Cases of DLBCL, NOS, diagnosed between 2000 
and 2014 were retrieved from the surgical pathology files 
and medical records of our institution. The study was 
approved by the University of Massachusetts Medical 
School Institutional Review Board. All DLBCLs were 
diagnosed and classified according to 2008 World 
Health Organization (WHO) criteria. Eighty-six DLBCL 
cases were included, composed of 46 female and 40 
male patients, with a median age of 70 years (range 
15-91 years). The primary sites involved by DLBCL in 
descending order of frequency included lymph node (32 
cases), soft tissue (18 cases), spleen (5 cases), bone (4 
cases), central nervous system (4 cases), skin (4 cases), 
salivary gland (3 cases), paranasal sinuses (3 cases), small 
bowel (3 cases), testis (3 cases), breast (2 cases), liver 
(2 cases), lung (2 cases), and bladder (1 case). All cases 
were negative for EBV-encoded RNA (EBER) by in situ 
hybridization study.
Immunohistochemistry and evaluation
Immunohistochemistry using a rabbit anti-PD-L1 
monoclonal antibody (clone E1L3N, #13684, Cell 
Signaling, Danvers, Massachusetts) was performed on 
5 μm-thick, formalin-fixed paraffin embedded (FFPE) 
tissue sections and tissue microarray sections using a 
Dako Autostainer (Dako Corporation, Carpinteria, CA) 
with antigen retrieval methods (0.01M citrate buffer at pH 
6.0) as described previously [5]. The UltraView Universal 
DAB Detection kit (#760-500, Ventana Medical Systems, 
Tuscon, AZ) was used according to the manufacturer 
instructions. Counterstaining was done as part of the 
automated staining protocol using hematoxylin (#760-
2021, Ventana Medical Systems).
All IHC-stained sections were evaluated and scored 
by two hematopathologists independently. Discrepancies 
in scoring (<10% of cases) were resolved by consensus 
conference between the two pathologists. Threshold values 
of 30% for BCL2, BCL6, CD10, and MUM1 staining 
were chosen reflecting routine clinical practice. MYC and 
Ki67 expression was recorded using a percentage scale 
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of positive tumor ranging from 0% to 100%. Staining 
intensity of PD-L1 was scored as follows: 0 (no staining), 
1+ (weak), 2+ (moderate), or 3+ (strong). Tumor cells 
exhibiting 2+ or 3+ membrane staining were recorded as a 
percentage of total tumor cellularity. PD-L1-positive non-
malignant cells as a percentage of total tumor cellularity 
was also recorded. Appropriate external positive (placenta) 
and negative (tonsil) controls were included with each 
staining run.
Clinical data
Patient demographics, clinical data, treatment and 
outcome information were obtained from the medical 
record. Clinical parameters included: presence of B 
symptoms, performance status, CBC, kidney and liver 
function tests, lactate dehydrogenase (LDH), bone 
marrow involvement, other extranodal sites involvement, 
bulky disease (>10cm), Ann Arbor stage, International 
Prognostic Index (IPI), positron emission tomography-
computed tomography (PET/CT) scan at diagnosis 
and after treatment, treatment history, response to first 
treatment (complete remission, partial remission, stable 
disease and progressive disease), major complications to 
treatment (e.g., neutropenic fever, sepsis, chronic heart 
failure, renal failure, etc), the dates of disease progression, 
relapse or death and cause of death.
Statistical analysis
Comparisons of clinical data between groups were 
carried out using the Fisher exact test, Chi-Square test, 
and survival analysis in SAS v9.3 (SAS Software, Cary, 
NC, USA) and R 3.2.1. Progression-free survival (PFS) 
was measured from the date of original diagnosis to the 
date of last follow-up or of the first progression, relapse 
or death, toxicity events being excluded. Overall survival 
(OS) was measured from the date of original diagnosis to 
the date of last follow-up or death from any cause. PFS 
and OS were estimated using the Kaplan-Meier method. 
Differences of PFS or OS at different PD-L1 expression 
levels were assessed using the Log-Rank tests at the two-
sided significance level of 0.05.
Age and sex-adjusted and multivariate analyses 
were conducted to evaluate the potential association 
between PD-L1 expression as well as other covariates 
with clinical outcomes. The stratified Cox proportional 
hazards model was used to determine hazard ratios and 
confidence intervals (CI) at the 95th confidence level. The 
variables included in multivariate analysis for OS were 
age, sex, expression of PD-L1, GCB/non-GCB type, 
stage and IPI. All of these variables had a P-value <0.1 
in the age- and sex-adjusted analysis. Occasional missing 
values in the data set did not appear to present significant 
problems in the modeling strategy. The proportional 
hazard assumptions were satisfied in both age and sex-
adjusted and multivariate analyses based on the log-log 
plots and Schoenfeld residuals method.
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